PMS-PIOGLITAZONE TABLET
Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Súhrn charakteristických
(SPC)
14-05-2018
Niektoré dokumenty týkajúce sa tohto produktu nie sú momentálne k dispozícii, môžete poslať požiadavku na náš zákaznícky servis a my vás upozorníme hneď, ako ich dokážeme získať.
Poslať žiadosť.
Poslať žiadosť.
Aktívna zložka:
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE)
Dostupné z:
PHARMASCIENCE INC
ATC kód:
A10BG03
INN (Medzinárodný Name):
PIOGLITAZONE
Dávkovanie:
30MG
Forma lieku:
TABLET
Zloženie:
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 30MG
Spôsob podávania:
ORAL
Počet v balení:
100
Typ predpisu:
Prescription
Terapeutické oblasti:
THIAZOLIDINEDIONES
Prehľad produktov:
Active ingredient group (AIG) number: 0141541002; AHFS:
Stav Autorizácia:
APPROVED
Dátum Autorizácia:
2007-12-05
Súhrn charakteristických
PRODUCT MONOGRAPH
PR
PMS-PIOGLITAZONE
Pioglitazone Hydrochloride Tablets
15 mg, 30 mg, 45 mg
USP
Anti-Diabetic Agent
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
Date of Revision:
May 14, 2018
www.pharmascience.com
Submission Control No: 215147
_pms-PIOGLITAZONE Product Monograph _
_Page 2 of 46_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
9
DRUG INTERACTIONS
.........................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................
15
OVERDOSAGE
.......................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 17
STORAGE AND STABILITY
.................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
24
PHARMACEUTICAL INFORMATION
.................................................................................
24
CLINICAL TRIALS
..........................................................
Prečítajte si celý dokument
